ABT

ABBOTT LABORATORIES

Healthcare | Mega Cap

$1.45

EPS Forecast

$12,975

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Abbott Q2 2026: EPS Up, Guidance Raised, and a Quiet Fortitude in the Medtech Engine

ABT, EPS, earnings surprise, EPS consensus, revenue forecast — a few keywords that feel like the drumbeat of this quarter. Abbott Laboratories (ABT) delivered a set of numbers that look sturdy enough to pass the bedside exam: solid top-line growth, a clear EPS trajectory, and an updated revenue forecast that keeps the picture intact even as the competitive landscape tightens.

What Abbott reported

Abbott’s second quarter of 2026 shows a company that can grow through volume and portfolio mix even while navigating a broad macro backdrop. The press release notes second-quarter sales up 13.0% on a reported basis, with a 4.8% rise in comparable or constant currency terms. On the bottom line, GAAP diluted EPS came in at $0.53, while adjusted diluted EPS stood at $1.31. Importantly, management raised the full-year 2026 guidance for adjusted EPS to a range of $5.45 to $5.60 (versus a prior $5.38 to $5.58), and reaffirmed a growth trajectory for comparable sales of 6.5% to 7.5%. Outside the numbers, the company highlighted a $2.1 billion return to shareholders in the form of dividends and buybacks.

The release arrived with a tone of execution rather than fireworks. Abbott’s structured mix—new and existing product lines, plus programs in diagnostics and device therapy—continues to drive the earnings profile, even as the company underlines ongoing investments in clinical programs and regulatory milestones.

Strategic milestones and near-term catalysts

The quarter carries several notable signals beyond the headline numbers. Abbott disclosed that enrollment in its TECTONIC U.S. pivotal trial for the Coronary Intravascular Lithotripsy (IVL) system was completed in April, a step that could matter for the durability of cardiovascular growth if the data translate into a meaningful clinical and regulatory outcome. In the same breath, Abbott highlighted late-breaking data presented at the Heart Rhythm Society conference around its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios, underscoring a pipeline of innovations that could support longer-term growth beyond the current quarter.

On the regulatory front, the company announced a CE Mark for its Libre Duo glucose-ketone biowearable sensor, a device designed to provide real-time visibility into glucose and ketone levels. Additionally, Abbott disclosed a submission to the U.S. FDA seeking approval for the Amulet 360 left atrial appendage (LAA) device. These milestones illustrate a diversified portfolio story: diagnostics, cardiovascular devices, and wearable technology all feeding into a broader growth narrative.

What this could portend for Abbott and its peers

From a macro perspective, Abbott’s Q2 results reinforce a narrative of resilience in the medtech ecosystem: solid demand for core products, a steady cadence of regulatory approvals, and a pipeline that blends device therapy with digital-health adjacent offerings. The EPS trajectory—an adjusted EPS of $1.31 for the quarter and a raised full-year target—suggests management sees ongoing leverage from product mix and operating discipline even as raw-material costs and inflationary pressures linger in the background.

For sector peers, the message is practical: a combination of growth in high-margin diagnostics, device-based therapies, and value-based outcomes programs can sustain earnings growth even when revenue forecasts are measured. The specific mix in Abbott’s numbers—strong sales growth paired with a higher EPS target—could influence how investors discount medtech cash flow, particularly if peer companies can demonstrate similar progress on pivotal trials, regulatory clearances, and portfolio optimization.

Numbers and narrative, laid out

  • Ticker: ABT
  • Revenue/Sales growth: 13.0% reported, 4.8% comparable
  • EPS: GAAP diluted EPS $0.53; adjusted diluted EPS $1.31
  • 2026 guidance – EPS: adjusted $5.45 to $5.60
  • 2026 guidance – revenue growth: comparable sales growth 6.5% to 7.5%
  • Shareholder returns: $2.1 billion returned via dividends and share repurchases
  • Key milestones: TECTONIC IVL pivotal trial enrollment complete; PFA/CSP data highlighted at HRS; Libre Duo CE Mark; Amulet 360 LAA FDA submission

Risks, nuances, and what to watch next

The numbers carry a practical caveat: the strength in the quarter rests on execution, not a single blockbuster product. Regulatory timelines remain a common source of delta between plan and reality. The TECTONIC trial readout, the pace of enrolling patients, and trial outcomes will be sequential catalysts that could materially influence the revenue forecast and earnings trajectory in 2027 and beyond. Regulatory acceptance of new devices and the adoption curve for wearable sensors like Libre Duo will hinge on real-world utility, reimbursement dynamics, and competitive differentiation.

From a market-macro lens, any incremental margin expansion will likely come from ongoing efficiency, favorable mix, and growth in high-margin devices versus commoditized diagnostics. If the sector peers can emulate Abbott’s discipline on operating costs while sustaining growth in new platforms, the path could support multiple expansion, not just a re-rating on top-line metrics.

Bottom line

Abbott’s Q2 2026 results present a durable earnings narrative: continued revenue growth, a clearly favorable EPS trajectory, and optionality from a diversified product pipeline and pivotal trials. The raised EPS guidance and reaffirmed revenue growth target signal confidence in near-term profitability, while the regulatory and clinical milestones offer a roadmap for longer-term growth. For ABT and its sector peers, the quarter functions as a reminder that in medtech, the balance sheet is increasingly a function of pipeline certainty and regulatory cadence as much as it is of quarterly sales momentum.